Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9777994 | 0.95 | XDH (0.41) | XDHALDH1A1GABRA1GABRB2MAPT | |
| SCHEMBL13978619 | 0.84 | XDH (0.44) | XDHALDH1A1GABRA1GABRB2MAPT | |
| SCHEMBL16950585 | 0.84 | TACR1 (0.37) | XDHALDH1A1GABRA1GABRB2MAPT | |
| SCHEMBL5449546 | 0.84 | XDH (0.35) | XDHALDH1A1GABRA1GABRB2MAPT | |
| SCHEMBL215399 | 0.80 | XDH (0.50) | XDHALDH1A1GABRA1GABRB2MAPT | |
| SCHEMBL1176840 | 0.78 | POLB (0.39) | XDHALDH1A1GABRA1GABRB2MAPT | |
| SCHEMBL28323722 | 0.78 | IDO1 (0.42) | IDO1 | |
| SCHEMBL7077104 | 0.77 | XDH (0.40) | XDHALDH1A1GABRA1GABRB2MAPT | |
| SCHEMBL30581261 | 0.77 | TAAR1 (0.50) | XDHALDH1A1GABRA1GABRB2MAPT | |
| SCHEMBL3185470 | 0.77 | TAAR1 (0.50) | XDHALDH1A1GABRA1GABRB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589111-B2 | Pt(IV) chemotherapeutic prodrug and controlled release thereof for treatment of tumors | PEKING UNIVERSITY (CN) | 2026-03-31 | — | — | US | claimed |
| WO-2022111541-A1 | PT(Ⅳ) CHEMOTHERAPEUTIC PRODRUG AND CONTROLLED RELEASE THEREOF FOR TREATMENT OF TUMORS | 北京大学 | 2022-06-02 | — | — | WO | disclosed |
| CN-113293010-A | Liquid-crystalline medium comprising polymerisable compounds | 默克专利股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-113046096-A | Liquid-crystalline medium comprising polymerisable compounds | 默克专利股份有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-8410151-B2 | Aminomethyl benzene derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-02 | — | — | US | disclosed |
| EP-2262782-B1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-04 | — | — | EP | disclosed |
| EP-2432554-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20110028449-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-03 | — | — | US | disclosed |
| WO-2010133528-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-25 | — | — | WO | disclosed |
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-11-25 | — | — | US | disclosed |
| EP-1013636-B1 | Preparation of allylic aromatic compounds | AMERSHAM HEALTH AS (NO) | 2003-07-09 | — | — | EP | disclosed |
| US-6284894-B1 | AROMATIC AMINE IS REACTED FIRST WITH A NITRITE AND THEN WITH AN ALLYLIC OLEFIN HAVING AN ELIMINATABLE TERMINAL SUBSTITUENT. | NYCOMED IMAGING AS (NO) | 2001-09-04 | — | — | US | disclosed |
| EP-1013636-A1 | Preparation of allylic aromatic compounds | NYCOMED IMAGING AS (NO) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, POLR2B | XDH 781/4885ALDH1A1 793/4885GABRA1 4298/4885 |
| US-12589111-B2 | Pt(IV) chemotherapeutic prodrug and controlled release thereof for treatment of tumors | PTGER4, PTGDR, PTGER3 | XDH 2904/4885ALDH1A1 3933/4885GABRA1 3521/4885 |
| US-20110028449-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | CD47, BRD4, BRD3 | XDH 334/4885ALDH1A1 984/4885GABRA1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.